Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Pharmacy
Published in: International Journal of Clinical Pharmacy 5/2019

01-10-2019 | Pharmacodynamics | Commentary

Optimising antimicrobial therapy through the use of Bayesian dosing programs

Authors: M. L. Avent, B. A. Rogers

Published in: International Journal of Clinical Pharmacy | Issue 5/2019

Login to get access

Abstract

The optimisation of antibiotic dosing therapy with therapeutic drug monitoring is widely recommended. The aim of therapeutic drug monitoring is to help the clinician to achieve target pharmacokinetic/pharmacodynamic parameters, maximising efficacy and minimising toxicity. Computerised programs, utilising the Bayesian estimation procedures, are able to achieve target concentrations in a greater percentage of patients earlier in the course of therapy compared to linear regression analysis and population methods. This article summarises various methods for dose optimisation of antibiotics with a focus on Bayesian programs.
Literature
1.
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509.CrossRef
2.
Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006.
3.
Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654–63.CrossRef
4.
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93–9.CrossRef
5.
Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents. 2002;19(4):355–8.CrossRef
6.
Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–51 (quiz 59).CrossRef
7.
Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J. 2011;41(6):441–9.CrossRef
8.
Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol. 1997;43(2):125–35.CrossRef
9.
Avent ML, Teoh J, Lees J, Eckert KA, Kirkpatrick CM. Comparing 3 methods of monitoring gentamicin concentrations in patients with febrile neutropenia. Ther Drug Monit. 2011;33(5):592–601.PubMed
10.
Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650–5.CrossRef
11.
Begg EJ, Barclay ML. Aminoglycosides: 50 years on. Br J Clin Pharmacol. 1995;39(6):597–603.CrossRef
12.
Paterson DL, Robson JM, Wagener MM, Peters M. Monitoring of serum aminoglycoside levels with once-daily dosing. Pathology. 1998;30(3):289–94.CrossRef
13.
Mohan M, Batty KT, Cooper JA, Wojnar-Horton RE, Ilett KF. Comparison of gentamicin dose estimates derived from manual calculations, the Australian ‘Therapeutic Guidelines: Antibiotic’ nomogram and the SeBA-GEN and DoseCalc software programs. Br J Clin Pharmacol. 2004;58(5):521–7.CrossRef
14.
Therapeutic Guidelines. Antibiotic. 16th ed. Melbourne, VIC: Therapeutic Guidelines; 2019.
15.
16.
Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM Jr, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. JAMA. 2016;315(17):1864–73.CrossRef
17.
Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52(1):9–22.CrossRef
18.
Turner RB, Kojiro K, Shephard EA, Won R, Chang E, Chan D, et al. Review and validation of Bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients. Pharmacotherapy. 2018;38(12):1174–83.CrossRef
19.
Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention—parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol. 2004;58(1):8–19.CrossRef
20.
Heil EL, Nicolau DP, Farkas A, Roberts JA, Thom KA. Pharmacodynamic target attainment for cefepime, meropenem and piperacillin/tazobactam using a pharmacokinetic/pharmacodynamic-based dosing calculator in critically ill patients. Antimicrob Agents Chemother. 2018;62:e01008-18.CrossRef
21.
Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D, et al. Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software. Ther Drug Monit. 2016;38(3):332–42.CrossRef
22.
Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62(2):e02042-17.CrossRef
23.
Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008;48(9):1081–91.CrossRef
24.
Burgard M, Sandaradura I, van Hal SJ, Stacey S, Hennig S. Evaluation of tobramycin exposure predictions in three Bayesian forecasting programmes compared with current clinical practice in children and adults with cystic fibrosis. Clin Pharmacokinet. 2018;57(8):1017–27.CrossRef
25.
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39.CrossRef
26.
Bayard DS, Jelliffe RW. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn. 2004;31(1):75–107.CrossRef
27.
Macdonald I, Staatz CE, Jelliffe RW, Thomson AH. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit. 2008;30(1):67–74.CrossRef
28.
Hennig S, Holthouse F, Staatz CE. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Clin Pharmacokinet. 2015;54(4):409–21.CrossRef
29.
Farkas A, Daroczi G, Villasurda P, Dolton M, Nakagaki M, Roberts JA. comparative evaluation of the predictive performances of three different structural population pharmacokinetic models to predict future voriconazole concentrations. Antimicrob Agents Chemother. 2016;60(11):6806–12.CrossRef
30.
Barras MA, Serisier D, Hennig S, Jess K, Norris RL. Bayesian estimation of tobramycin exposure in patients with cystic fibrosis. Antimicrob Agents Chemother. 2016;60(11):6698–702.CrossRef
Metadata
Title
Optimising antimicrobial therapy through the use of Bayesian dosing programs
Authors
M. L. Avent
B. A. Rogers
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 5/2019
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00886-4

Other articles of this Issue 5/2019

International Journal of Clinical Pharmacy 5/2019 Go to the issue

Research Article

Healthcare personnel’s experience of reporting adverse drug reactions in Baghdad city: cross-sectional study

Research Article

Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016

Research Article

Experience with a colorectal cancer campaign in Swiss pharmacies

Research Article

Exploring variables associated with medication non-adherence in patients with COPD

Research Article

Stakeholders views of medicines administration by pharmacy technicians on mental health inpatient wards

Research Article

Evaluating the Connect with Pharmacy web-based intervention to reduce hospital readmission for older people
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits